Literature DB >> 7641183

Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint.

M T Hawn1, A Umar, J M Carethers, G Marra, T A Kunkel, C R Boland, M Koi.   

Abstract

The human colon tumor cell line HCT116 is deficient in wild-type hMLH1, is defective in mismatch repair (MMR), exhibits microsatellite instability, and is tolerant to N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). Transferring a normal copy of hMLH1 on chromosome 3 into the cell line restores MMR activity, stabilizes microsatellite loci, and increases the sensitivity of the cell to MNNG. Previous studies in other cell lines tolerant to alkylating agents such as MNNG or N-methylnitrosourea have shown cross-tolerance to 6-thioguanine (6TG), leading to a hypothesis that tolerance to MNNG or 6TG may be the result of MMR deficiency. To test this hypothesis, we studied the effects of 6TG on the MNNG-tolerant, MMR-deficient HCT116 cell line and its MNNG-sensitive, MMR-proficient, MNNG-tolerant, and MMR-deficient derivatives. Continuous exposure to low doses of 6TG (0.31-1.25 micrograms/ml) had no apparent effect on colony-forming ability (CFA) in MNNG-tolerant, MMR-deficient cells, whereas MNNG-sensitive, MMR-proficient cells exhibited a dose-dependent decrease in CFA. Growth kinetics and cell cycle analysis revealed that the growth of 6TG-treated HCT116 + chr3 cells was arrested at G2 after exposure to low dose of 6TG. In contrast, the same exposure to 6TG did not induce G2 arrest but rather a G1 delay in HCT116 and HCT116 + chr2. To obtain further evidence for the role of MMR on 6TG and MNNG toxicity, we isolated an MNNG-resistant revertant clone, M2, from the MNNG-sensitive, MMR-proficient HCT116 + chr3 cell line and characterized the MMR activity, hMLH1 status, and 6TG response. The results showed that M2 cells lost MMR activity as well as the previously introduced normal hMLH1 gene. Restoration of the CFA of M2 and an absence of G2 arrest were observed after treatment with low doses of 6TG. These results suggest that the mismatch repair system interacts with the G2 checkpoint in response to 6TG or MNNG-induced DNA lesions. The results further suggest that any agent that induces DNA mispairs will cause G2 arrest in MMR-proficient cells but not in MMR-deficient cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7641183

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  82 in total

1.  Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis.

Authors:  J Wu; L Gu; H Wang; N E Geacintov; G M Li
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

2.  hMutSalpha forms an ATP-dependent complex with hMutLalpha and hMutLbeta on DNA.

Authors:  Guido Plotz; Jochen Raedle; Angela Brieger; Jörg Trojan; Stefan Zeuzem
Journal:  Nucleic Acids Res       Date:  2002-02-01       Impact factor: 16.971

3.  Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage.

Authors:  Eugene S Kandel; Jennifer Skeen; Nathan Majewski; Antonio Di Cristofano; Pier Paolo Pandolfi; Claudine S Feliciano; Andrei Gartel; Nissim Hay
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

4.  Dimerization of MLH1 and PMS2 limits nuclear localization of MutLalpha.

Authors:  Xiaosheng Wu; Jeffrey L Platt; Marilia Cascalho
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

Review 5.  Microsatellite instability in colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

6.  Honokiol radiosensitizes colorectal cancer cells: enhanced activity in cells with mismatch repair defects.

Authors:  Zhiyun He; Dharmalingam Subramaniam; Satish Ramalingam; Animesh Dhar; Russell G Postier; Shahid Umar; Youcheng Zhang; Shrikant Anant
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-08-11       Impact factor: 4.052

7.  Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct.

Authors:  D R Duckett; J T Drummond; A I Murchie; J T Reardon; A Sancar; D M Lilley; P Modrich
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 8.  Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer.

Authors:  Christopher D Heinen
Journal:  DNA Repair (Amst)       Date:  2015-12-02

9.  Clement Richard Boland, Jr., MD: a conversation with the editor. Interview by William Clifford Roberts.

Authors:  Clement Richard Boland
Journal:  Proc (Bayl Univ Med Cent)       Date:  2004-10

10.  Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.

Authors:  J M Carethers
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.